Abstract 4P
Background
Complications of immediate breast reconstruction caused by chemotherapy or radiotherapy have been debated, but these complications may delay the end of adjuvant treatment and subsequently increase the recurrence. The purpose of this study was to identify risk factors of tissue expander or implant removal and difference of duration from mastectomy to tissue expander or implant removal.
Methods
We conducted a retrospective study of total 11362 breast cancer patients between 2012 and 2017 who were identified in Samsung Medical Center. Eligible patients were total 1091 female breast cancer patients after nipple sparing mastectomy or skin sparing mastectomy with tissue expander or direct implant insertion.
Results
602 (55.2%) patients (group A) have not chemotherapy (CTx), 61 (5.6%) patients (group B) have neoadjuvant CTx and 428 (39.2%) patients (group C) have adjuvant CTx. 897 (82.2%) patients (group D) have not radiotherapy (RTx), 194 (17.8%) patients (group E) have RTx. 1050 (96.2%) patients (group N) have not tissue expander or implant removal and 41 (3.8%) patients (group R) have tissue expander or implant removal. Baseline and pathologic characteristics of patients were not different except N stage between group N and group R. Univariate analysis showed increased pathologic N stage was significantly associated tissue expander or implant removal. (HR = 14.769, 95% CI = 4.338 to 50.284). Tissue expander or implant removal occurred more group B (6.6%) than group A (2.0%) (HR = 3.450, 95% CI = 1.078 to 11.048), more group C (5.8%) than group A (HR = 3.050, 95% CI = 1.515 to 6.141) and more group E (8.8%) than group D (2.7%) (HR = 3.494, 95% CI = 1.839 to 6.639). In multivariate analysis, N stage decreases, tissue expander or implant removal occurred earlier (P < .05). Median time of duration from operation to tissue expander or implant removal was 495 days (range 10-2423 days).
Conclusions
Immediate reconstruction with tissue expander or implant after mastectomy may be a choice of treatment option even in breast cancer patients who will be received chemotherapy or radiotherapy. These results will aid preoperative counselling to patients who are concerned about complication of immediate reconstruction caused by chemotherapy or radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract